HMGA2 translocations were described in 45% of tumors not containing MED12 mutations [10], suggesting multiple, less prevalent, genetic aberrations are responsible for the remaining 55% of non-MED12 altered leiomyomas. This evidence concerns the gene MED12 and leiomyoma.